Skip to main content
Premium Trial:

Request an Annual Quote

Sense Biodetection, Bio Nuclear Diagnostics Ink Canada Distribution Deal for COVID MDx Test

NEW YORK – Boston-based molecular diagnostics developer Sense Biodetection has signed a distribution deal with Bio Nuclear Diagnostics, a medical distributor based in Cambridge, UK, and Toronto. The nonexclusive agreement enables Bio Nuclear Diagnostics to distribute the Sense Veros COVID-19 test in Canada.

The Veros is a disposable, instrument-free, point-of-care molecular diagnostic test that performs isothermal nucleic acid amplification in 15 minutes using a proprietary method.

The distribution deal will enable Bio Nuclear Diagnostics to supply customers with Veros tests immediately upon Canadian regulatory approval, the firms said in a statement.

"The North American market is very important for Sense, so being able to distribute in Canada with a partner of the caliber of Bio Nuclear Diagnostics provides a solid foundation to serve providers and their patients," Ryan Roberts, Sense's chief commercial officer, said in a statement.

Rakesh Nayyar, director of business development at BND, said in a statement, "By extending rapid, highly accurate molecular testing closer to patients, without constraints of instruments or even external power, we're optimistic about the opportunity to help providers improve care, and help facilities relieve bottlenecks and constraints typically associated with the traditional lab model."

Backed by investment from Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health, and Mercia Asset Management, Sense has launched its CE-marked Veros COVID-19 product in select countries in Europe and South America and is also building a portfolio of tests for other diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.